Yeni Kuşak Antikoagülan ve Antiagreganların Komplikasyonlarının Vaka Sunumlarıyla İncelenmesi
Özet
Modern tıbbın ilerlemesi ile geleneksel yaklaşımlarla hayatımıza girmiş ve günümüzde de aktif olarak kullanımı devam eden antikoagülan ve antiagreganların son yıllarda yaşadığı gelişmeler ışığında karşımıza çıkan yeni kuşak antikoagülan ve antiagreganlar önceki bölümlerde geniş ölçekte ele alındı.
Getirdikleri avantajların yanı sıra her ilacın olduğu gibi bu grupta da karşımıza çeşitli komplikasyonlar çıkmaktadır. Bu bölümde sık karşılaşılan ve klinik anlamda öneme sahip olan çeşitli komplikasyonlar ile ilgili yapılan vaka bildirimlerine değineceğiz. Bu vakaları anlatarak, klinik uygulamada karşılaşılabilecek potansiyel riskleri ve bu risklerin etkin yönetim stratejilerini tartışmayı amaçlıyoruz. Bu şekilde, pratik klinik bilgilerin yanı sıra klinik düşünme ve karar verme becerilerini geliştirmeyi hedefliyoruz.
With the advancement of modern medicine, anticoagulants and antiplatelet agents have been integrated into our lives alongside traditional approaches and continue to be actively used today. In light of the developments in recent years, new generation anticoagulants and antiplatelet agents have been discussed in depth in previous sections.
Despite the advantages they bring, various complications arise with these medications, as with any drug. In this section, we will address commonly encountered complications that are clinically significant, along with case reports related to them. By discussing these cases, we aim to highlight potential risks that may be encountered in clinical practice and effective management strategies for these risks. In this way, we aim to develop practical clinical knowledge as well as clinical thinking and decision-making skills.
Referanslar
Sare, G., F. Lloyd, and M. Stower, Life-threatening haemorrhage after extracorporeal shockwave lithotripsy in a patient taking clopidogrel. BJU international, 2002. 90(4).
Streem, S.B., Contemporary clinical practice of shock wave lithotripsy: a reevaluation of contraindications. The Journal of urology, 1997. 157(4): p. 1197-1203.
Zhang, J.Q., J.R. Fielding, and K.H. Zou, Etiology of spontaneous perirenal hemorrhage: a meta-analysis. The Journal of urology, 2002. 167(4): p. 1593-1596.
Lee, P.S., et al., A Case of Spontaneous Perinephric Hematoma From Rivaroxaban. Cureus, 2022. 14(9).
Shaw, D.J., et al., An Inconspicuous Offender: Apixaban-Induced Anticoagulant-Related Nephropathy. Cureus, 2023. 15(9).
Chen, S., et al., Anticoagulant-related nephropathy induced by direct-acting oral anticoagulants: Clinical characteristics, treatments and outcomes. Thrombosis Research, 2023. 222: p. 20-23.
Raghavan, N., et al., Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug metabolism and disposition, 2009. 37(1): p. 74-81.
Brodsky, S.V., Anticoagulants and acute kidney injury: clinical and pathology considerations. Kidney research and clinical practice, 2014. 33(4): p. 174-180.
Abdulhadi, B., et al., Novel oral anticoagulant and kidney injury: apixaban-related acute interstitial nephritis. Case Reports, 2017. 2017: p. bcr-2017-221641.
Stangier, J., et al., The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. British journal of clinical pharmacology, 2007. 64(3): p. 292-303.
Işık, F., Ü. İnci, and A. Akyüz, Dabigatran Kullanımı Sonrası Yüksek INR ve aPTT'ye Bağlı Ciddi Üriner Kanama: Olgu Sunumu. Hemoglobin (gr/dl), 2023. 4(7.4): p. 8.5.
Dibek, Y., O. Karakılıç, and F.H. Turgut, Apiksaban Kullanımı Sonucu Gelişen Psoas Kası Kanamasına Bağlı Akut Böbrek Yetmezliği: Olgu Sunumu. The Medical Journal of Mustafa Kemal University, 2019. 10(38): p. 108-110.
Granger, C.B., et al., Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 2011. 365(11): p. 981-992.
Referanslar
Sare, G., F. Lloyd, and M. Stower, Life-threatening haemorrhage after extracorporeal shockwave lithotripsy in a patient taking clopidogrel. BJU international, 2002. 90(4).
Streem, S.B., Contemporary clinical practice of shock wave lithotripsy: a reevaluation of contraindications. The Journal of urology, 1997. 157(4): p. 1197-1203.
Zhang, J.Q., J.R. Fielding, and K.H. Zou, Etiology of spontaneous perirenal hemorrhage: a meta-analysis. The Journal of urology, 2002. 167(4): p. 1593-1596.
Lee, P.S., et al., A Case of Spontaneous Perinephric Hematoma From Rivaroxaban. Cureus, 2022. 14(9).
Shaw, D.J., et al., An Inconspicuous Offender: Apixaban-Induced Anticoagulant-Related Nephropathy. Cureus, 2023. 15(9).
Chen, S., et al., Anticoagulant-related nephropathy induced by direct-acting oral anticoagulants: Clinical characteristics, treatments and outcomes. Thrombosis Research, 2023. 222: p. 20-23.
Raghavan, N., et al., Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug metabolism and disposition, 2009. 37(1): p. 74-81.
Brodsky, S.V., Anticoagulants and acute kidney injury: clinical and pathology considerations. Kidney research and clinical practice, 2014. 33(4): p. 174-180.
Abdulhadi, B., et al., Novel oral anticoagulant and kidney injury: apixaban-related acute interstitial nephritis. Case Reports, 2017. 2017: p. bcr-2017-221641.
Stangier, J., et al., The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. British journal of clinical pharmacology, 2007. 64(3): p. 292-303.
Işık, F., Ü. İnci, and A. Akyüz, Dabigatran Kullanımı Sonrası Yüksek INR ve aPTT'ye Bağlı Ciddi Üriner Kanama: Olgu Sunumu. Hemoglobin (gr/dl), 2023. 4(7.4): p. 8.5.
Dibek, Y., O. Karakılıç, and F.H. Turgut, Apiksaban Kullanımı Sonucu Gelişen Psoas Kası Kanamasına Bağlı Akut Böbrek Yetmezliği: Olgu Sunumu. The Medical Journal of Mustafa Kemal University, 2019. 10(38): p. 108-110.
Granger, C.B., et al., Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine, 2011. 365(11): p. 981-992.
